94-19-9

Usage

Originator

Sul-Spansion,SKF,US,1956

Manufacturing Process

0.163 mol of 2-amino-5-ethyl-1,3,4-thiadiazole was covered with 43 parts of anhydrous pyridine. To the mixture was added 50 parts (0.214 mol) of pacetylaminobenzenesulfonyl chloride with vigorous shaking at 50°C to 60°C. The reaction mixture was then heated to 125°C. When the mixture had cooled somewhat it was placed in a Claisen flask and 27.6 parts (0.69 mol) of sodium hydroxide dissolved in 110 parts of water was added through a dropping funnel while distilling off a mixture of pyridine and water. The distillation was stopped when the temperature reached 100°C and the residual liquor in the flask heated at 95°C for 30 minutes.The reaction mixture was then poured into 1,650 parts of hot water, the pH adjusted to 8 to 9, decolorizing charcoal was added and the whole was heated on the steam for 15 minutes. The charcoal was filtered off and the hot filtrate neutralized and cooled. The 2-(sulfanilamido)-5-ethyl-1,3,4-thiadiazole was purified by repeated crystallization from boiling water.

Therapeutic Function

Antibacterial

InChI:InChI=1/C10H12N4O2S2/c1-2-9-12-13-10(17-9)14-18(15,16)8-5-3-7(11)4-6-8/h3-6H,2,11H2,1H3,(H,13,14)

Upstream product

• 76170-72-4 2-(4-Nitrobenzenesulfonamido)-5-ethyl-1,3,4-thiadiazole 
• 1037-51-0 N-(4-(N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamoyl)phenyl)acetamide 
• 100-05-0 4-nitrobenzenediazonium chloride 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 121-61-9 p-acetylaminobenzenesulfonamide 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 

Downstream Products

• 109698-58-0 4-acetylamino-2-hydroxy-benzoic acid-[4-(5-ethyl-[1,3,4]thiadiazol-2-ylsulfamoyl)-anilide] 
• 109588-73-0 4-amino-2-hydroxy-benzoic acid-[4-(5-ethyl-[1,3,4]thiadiazol-2-ylsulfamoyl)-anilide] 
• 104912-11-0 acetyl-(ethyl-[1,3,4]thiadiazol-2-yl)-sulfanilyl-amine 
• 132777-51-6 N-(2,4-dinitro-phenyl)-sulfanilic acid-(5-ethyl-[1,3,4]thiadiazol-2-ylamide) 
• 15018-98-1 4-amino-3,5-dibromo-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-benzenesulfonamide 
• 16588-44-6 N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-4-(8-hydroxy-quinolin-5-ylazo)-benzenesulfonamide 
• 41334-31-0 N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-4-[(2,4,6-trioxo-tetrahydro-pyrimidin-5-ylidene)-hydrazino]-benzenesulfonamide 
• 41334-32-1 4-[(4,6-dioxo-2-thioxo-tetrahydro-pyrimidin-5-ylidene)-hydrazino]-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-benzenesulfonamide 
• 41371-06-6 N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-4-(5-ethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylazo)-benzenesulfonamide 
• 41334-09-2 4-(5-ethyl-4,6-dioxo-2-thioxo-hexahydro-pyrimidin-5-ylazo)-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-benzenesulfonamide 
• 41334-07-0 N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-4-(5-isopropyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylazo)-benzenesulfonamide 
• 41334-10-5 N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-4-(5-isopropyl-4,6-dioxo-2-thioxo-hexahydro-pyrimidin-5-ylazo)-benzenesulfonamide 
• 41334-08-1 4-(5-benzyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylazo)-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-benzenesulfonamide 
• 73008-54-5 4-(2-benzylidenehydrazino-4-phenyl-thiazol-5-ylazo)-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-benzenesulfonamide 

Relevant academic research and scientific papers

Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists

Prostanoid receptor EP2 is emerging as a novel target for development of anti-inflammatory drugs for the treatment of chronic neurodegenerative and peripheral diseases; however, the availability of EP2 antagonist probes for exploration of peripheral disease models is very limited. We now report identification and characterization of a novel chemical class of compounds that show nanomolar potency and competitive antagonism of the EP2 receptor. A compound in this class, TG6-129, showed prolonged plasma half-life and did not cross the blood-brain barrier. This compound also suppressed the induction of inflammatory mRNA markers in a macrophage cell line upon activation of EP2. Thus, this compound could be useful as a probe for a variety of peripheral chronic inflammatory diseases such as rheumatoid arthritis and chronic obstructive pulmonary disease, in which EP2 appears to play a pathogenic role.

Development of sulfonamide AKT PH domain inhibitors

Disruption of the phosphatidylinositol 3-kinase/AKT signaling pathway can lead to apoptosis in cancer cells. Previously we identified a lead sulfonamide that selectively bound to the pleckstrin homology (PH) domain of AKT and induced apoptosis when present at low micromolar concentrations. To examine the effects of structural modification, a set of sulfonamides related to the lead compound was designed, synthesized, and tested for binding to the expressed PH domain of AKT using a surface plasmon resonance-based competitive binding assay. Cellular activity was determined by means of an assay for pAKT production and a cell killing assay using BxPC-3 cells. The most active compounds in the set are lipophilic and possess an aliphatic chain of the proper length. Results were interpreted with the aid of computational modeling. This paper represents the first structure-activity relationship (SAR) study of a large family of AKT PH domain inhibitors. Information obtained will be used in the design of the next generation of inhibitors of AKT PH domain function.

SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME

Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.

Process for formulating a synthetic drug for use in animal feed, and resulting formulation

A method of formulating a synthetic drug for use in animal feed, for the purpose of reducing carry-over of the synthetic drug to subsequent lots of animal feed in the feed mill.